Cargando…

Productivity Loss and Indirect Costs for Patients Newly Diagnosed with Early- versus Late-Stage Cancer in the USA: A Large-Scale Observational Research Study

BACKGROUND: The total economic burden of cancer reflects direct and indirect costs, including productivity loss due to employment change, absenteeism, and presenteeism of patients and caregivers. OBJECTIVE: This study estimated the magnitude of employment decrease, work absence (WA), short-term disa...

Descripción completa

Detalles Bibliográficos
Autores principales: Cong, Ze, Tran, Oth, Nelson, James, Silver, Monica, Chung, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596506/
https://www.ncbi.nlm.nih.gov/pubmed/36040661
http://dx.doi.org/10.1007/s40258-022-00753-w
_version_ 1784815886246346752
author Cong, Ze
Tran, Oth
Nelson, James
Silver, Monica
Chung, Karen
author_facet Cong, Ze
Tran, Oth
Nelson, James
Silver, Monica
Chung, Karen
author_sort Cong, Ze
collection PubMed
description BACKGROUND: The total economic burden of cancer reflects direct and indirect costs, including productivity loss due to employment change, absenteeism, and presenteeism of patients and caregivers. OBJECTIVE: This study estimated the magnitude of employment decrease, work absence (WA), short-term disability (STD), long-term disability (LTD), and associated indirect costs among employees newly diagnosed with metastatic versus non-metastatic cancer in the USA. METHODS: IBM(®) MarketScan(®) Commercial Claims and Encounters and Health and Productivity Management databases were used to identify employees aged 18–64 years and newly diagnosed with any cancer from 2009 to 2019. Proportions of patients with employment decrease, WA, STD, and LTD claims, and number of days missing from work were summarized by metastatic status during the first 12 months after diagnosis and the entire follow-up period. Subgroup analyses were conducted by age (< 50 years, ≥ 50 years) and cancer type (breast, lung, colon, pancreatic, and liver cancer). RESULTS: During the first year after diagnosis, compared to patients without metastases, significantly higher proportions of patients with metastases had employment decrease and STD or LTD claims (p < 0.001). The mean total number of days missing from work for patients with versus without metastases was 33.39 versus 14.91 (ratio = 2.40), 64.05 versus 27.15 (ratio = 2.36), and 105.93 versus 46.29 (ratio = 2.29) days within 3, 6, and 12 months after diagnosis, respectively. Estimates of indirect cost differences between the two groups ranged from $6,877 to $22,283 in the first year. CONCLUSION: Earlier detection of cancer may reduce productivity loss of patients and indirect costs by initiating treatment before cancer progresses to late stage. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40258-022-00753-w.
format Online
Article
Text
id pubmed-9596506
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-95965062022-10-27 Productivity Loss and Indirect Costs for Patients Newly Diagnosed with Early- versus Late-Stage Cancer in the USA: A Large-Scale Observational Research Study Cong, Ze Tran, Oth Nelson, James Silver, Monica Chung, Karen Appl Health Econ Health Policy Original Research Article BACKGROUND: The total economic burden of cancer reflects direct and indirect costs, including productivity loss due to employment change, absenteeism, and presenteeism of patients and caregivers. OBJECTIVE: This study estimated the magnitude of employment decrease, work absence (WA), short-term disability (STD), long-term disability (LTD), and associated indirect costs among employees newly diagnosed with metastatic versus non-metastatic cancer in the USA. METHODS: IBM(®) MarketScan(®) Commercial Claims and Encounters and Health and Productivity Management databases were used to identify employees aged 18–64 years and newly diagnosed with any cancer from 2009 to 2019. Proportions of patients with employment decrease, WA, STD, and LTD claims, and number of days missing from work were summarized by metastatic status during the first 12 months after diagnosis and the entire follow-up period. Subgroup analyses were conducted by age (< 50 years, ≥ 50 years) and cancer type (breast, lung, colon, pancreatic, and liver cancer). RESULTS: During the first year after diagnosis, compared to patients without metastases, significantly higher proportions of patients with metastases had employment decrease and STD or LTD claims (p < 0.001). The mean total number of days missing from work for patients with versus without metastases was 33.39 versus 14.91 (ratio = 2.40), 64.05 versus 27.15 (ratio = 2.36), and 105.93 versus 46.29 (ratio = 2.29) days within 3, 6, and 12 months after diagnosis, respectively. Estimates of indirect cost differences between the two groups ranged from $6,877 to $22,283 in the first year. CONCLUSION: Earlier detection of cancer may reduce productivity loss of patients and indirect costs by initiating treatment before cancer progresses to late stage. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40258-022-00753-w. Springer International Publishing 2022-08-30 2022 /pmc/articles/PMC9596506/ /pubmed/36040661 http://dx.doi.org/10.1007/s40258-022-00753-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
Cong, Ze
Tran, Oth
Nelson, James
Silver, Monica
Chung, Karen
Productivity Loss and Indirect Costs for Patients Newly Diagnosed with Early- versus Late-Stage Cancer in the USA: A Large-Scale Observational Research Study
title Productivity Loss and Indirect Costs for Patients Newly Diagnosed with Early- versus Late-Stage Cancer in the USA: A Large-Scale Observational Research Study
title_full Productivity Loss and Indirect Costs for Patients Newly Diagnosed with Early- versus Late-Stage Cancer in the USA: A Large-Scale Observational Research Study
title_fullStr Productivity Loss and Indirect Costs for Patients Newly Diagnosed with Early- versus Late-Stage Cancer in the USA: A Large-Scale Observational Research Study
title_full_unstemmed Productivity Loss and Indirect Costs for Patients Newly Diagnosed with Early- versus Late-Stage Cancer in the USA: A Large-Scale Observational Research Study
title_short Productivity Loss and Indirect Costs for Patients Newly Diagnosed with Early- versus Late-Stage Cancer in the USA: A Large-Scale Observational Research Study
title_sort productivity loss and indirect costs for patients newly diagnosed with early- versus late-stage cancer in the usa: a large-scale observational research study
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596506/
https://www.ncbi.nlm.nih.gov/pubmed/36040661
http://dx.doi.org/10.1007/s40258-022-00753-w
work_keys_str_mv AT congze productivitylossandindirectcostsforpatientsnewlydiagnosedwithearlyversuslatestagecancerintheusaalargescaleobservationalresearchstudy
AT tranoth productivitylossandindirectcostsforpatientsnewlydiagnosedwithearlyversuslatestagecancerintheusaalargescaleobservationalresearchstudy
AT nelsonjames productivitylossandindirectcostsforpatientsnewlydiagnosedwithearlyversuslatestagecancerintheusaalargescaleobservationalresearchstudy
AT silvermonica productivitylossandindirectcostsforpatientsnewlydiagnosedwithearlyversuslatestagecancerintheusaalargescaleobservationalresearchstudy
AT chungkaren productivitylossandindirectcostsforpatientsnewlydiagnosedwithearlyversuslatestagecancerintheusaalargescaleobservationalresearchstudy